BREAKING: Novo Nordisk's CagriSema fails to hit 25% weightloss benchmark in Phase 3 readout. Novo’s stock $NVO crashed by as much as 26% pre-market Friday.
https://endpts.com/novo-reveals-23-weight-loss-with-cagrisema-which-is-below-expectations/?utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=bluesky&utm_content=&utm_term=
https://endpts.com/novo-reveals-23-weight-loss-with-cagrisema-which-is-below-expectations/?utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=bluesky&utm_content=&utm_term=
Comments